Refining basal insulin therapy: what have we learned in the age of analogues?
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: The basal insulin analogues glargine and detemir have been subject to a series of trials comparing their clinical profiles to the conventional preparation, neutral protamine Hagedorn (NPH). Careful review of these trials provides opportunities to learn clinically useful lessons about these insulins. Methods: MedLine‐indexed trials comparing glargine or detemir to NPH were scrutinized for control, tolerability and dose data. Separate considerations were made for types 1 and 2 diabetes, and for basal–bolus and basal plus oral glucose‐lowering drugs (OGLD) therapy. Attention was paid to dosing schedules and 24‐h glycaemic profiles. Results: Collectively, the trials demonstrated an improved balance between glycaemic control and tolerability for both analogues compared to NPH, regardless of regimen and diabetes type. Neither once‐daily glargine nor detemir reliably provides 24‐h basal insulin replacement in all patients with type 1 diabetes; a waning of effect frequently obliges twice‐daily administration. When added to OGLDs in type 2 diabetes, goal‐titrated once‐daily basal insulin generally lowered HbA 1c by ∼1.5%, whereas twice‐daily administration tended to increase insulin dose disproportionately to improvement in control. Hence, adding bolus insulin may be a preferable intensification method to dividing the basal dose. Varying injection time or dividing the basal insulin dose predictably affects the pattern of hypoglycaemia and bolus dose requirements. Morning administration tends to require higher dosing than evening administration. Conclusions: Scrutiny of trials involving glargine and detemir has increased our understanding of how best to dose basal insulins. An individualized approach is still necessary however, and several questions remain that require further research. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818 · cited 1×
“[11] reported a mean duration of action of 20.”
BackgroundHirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Hermansen, K., Fontaine, P., Kukolja, K. K., Peterkova, V., Leth, G., & Gall, M.-A. (2004) · Diabetologia · doi:10.1007/s00125-004-1365-z · Cited by 365
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294
Klein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251 · cited 1×
“A subsequent study by Klein and colleagues [13] has suggested that the mean pharmacodynamic profiles of the two analogues in type 2 diabetes are actually very similar at clinically relevant doses.”
BackgroundRaskin, P., Klaff, L., Bergenstal, R., Hallé, J. P., Donley, D., & Mecca, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1666 · Cited by 250
Cited by
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Insulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Self-citation
Metadata
- Authors
- DeVries, J. H., Nattrass, M., & Pieber, T. R.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2007-07-31
- Volume
- 23
- Issue
- 6
- Pages
- 441-454
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2154661744
- Cited by
- 94
- References
- 15
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Refining basal insulin therapy: what have we learned in the age of analogues? https://app.cochat.ai/papers/10.1002/dmrr.762
- The paper
- DeVries, J. H., Nattrass, M., & Pieber, T. R. (2007). Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.762
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.